Report Library
All Reports
Colorectal Cancer KOL Interview – US
October 29, 2020
This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for colorectal cancer. Disease stratifications by staging and expression profile of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Keytruda, Braftovi, Opdivo, Avastin (and bevacizumab biosimilars), Herceptin (and trastuzumab biosimilars), Lonsurf, and Erbitux.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.
For our disclosures, please read the Biomedtracker Research Standards.| Indications Covered: | Colorectal Cancer (CRC) |
Additional Resources:
- Disease Analysis: Colorectal Cancer
- 2020 Biomedtracker / Datamonitor Healthcare Post-ESMO Report
- Top 10 Best-Selling Drugs of 2019
- Key Potential Drug Launches in 2021
- 2020 Biomedtracker / Datamonitor Healthcare Post-AACR Report
- 2020 Biomedtracker / Datamonitor Healthcare Post-ASCO Report
- Potential Pivots in 2020
- Non-Small Cell Lung Cancer (NSCLC) KOL Interview – UK
- HER2+ Breast Cancer KOL Interview – UK
- HER2+ Breast Cancer KOL Interview – US